Allegra Medical Technologies (ASX:AMT) Cash-to-Debt : 0.11 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Allegra Medical Technologies Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Allegra Medical Technologies's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.11.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Allegra Medical Technologies couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Allegra Medical Technologies's Cash-to-Debt or its related term are showing as below:

ASX:AMT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 2.29 Max: No Debt
Current: 0.11

During the past 13 years, Allegra Medical Technologies's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 2.29.

ASX:AMT's Cash-to-Debt is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.845 vs ASX:AMT: 0.11

Allegra Medical Technologies Cash-to-Debt Historical Data

The historical data trend for Allegra Medical Technologies's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Allegra Medical Technologies Cash-to-Debt Chart

Allegra Medical Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

12.81

4.53

1.02

0.09

Allegra Medical Technologies Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.28	0.09	0.21	-	0.11

Competitive Comparison of Allegra Medical Technologies's Cash-to-Debt

For the Medical Devices subindustry, Allegra Medical Technologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allegra Medical Technologies's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Allegra Medical Technologies's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Allegra Medical Technologies's Cash-to-Debt falls into.

Allegra Medical Technologies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Allegra Medical Technologies's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.001	/	(0.45	+	2.678)
	=	0.00

Allegra Medical Technologies's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.154	/	(1.454	+	0)
	=	0.11

Allegra Medical Technologies (ASX:AMT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Allegra Medical Technologies Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Allegra Medical Technologies's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Allegra Medical Technologies (ASX:AMT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Allegra Medical Technologies Ltd (ASX:AMT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

18-20 Orion Road, Level 8, Lane Cove West, Sydney, NSW, AUS, 2066

Website

https://www.allegraorthopaedics.com

Allegra Medical Technologies Ltd is engaged in the research, product development, and manufacturing of medical devices including prosthetic implant tools. It offers adult and adolescent clavicle fixation systems and pins; shoulder implants; hand fracture plates and ulna heads, compression screws, distal radius systems, and hand fracture systems; hip stems and heads, CSF cups, and evolution and resurfacing hip products; and knee replacement systems among others. It operates in two segments Orthopaedics Division, which derives the majority of its revenue sells and distributes its portfolio of medical device products. Innovation Division which invests resources into the development and commercialization of new products to take to market.